U.S. Markets open in 1 hr 21 mins
  • S&P Futures

    4,140.25
    -15.25 (-0.37%)
     
  • Dow Futures

    33,834.00
    -124.00 (-0.37%)
     
  • Nasdaq Futures

    13,860.75
    -36.50 (-0.26%)
     
  • Russell 2000 Futures

    2,213.70
    -15.60 (-0.70%)
     
  • Crude Oil

    63.62
    +0.24 (+0.38%)
     
  • Gold

    1,773.60
    +3.00 (+0.17%)
     
  • Silver

    25.99
    +0.15 (+0.59%)
     
  • EUR/USD

    1.2055
    +0.0015 (+0.1206%)
     
  • 10-Yr Bond

    1.6010
    0.0000 (0.00%)
     
  • Vix

    18.35
    +2.10 (+12.92%)
     
  • GBP/USD

    1.3967
    -0.0017 (-0.1229%)
     
  • USD/JPY

    108.3970
    +0.2470 (+0.2284%)
     
  • BTC-USD

    56,111.86
    -708.24 (-1.25%)
     
  • CMC Crypto 200

    1,268.28
    -30.68 (-2.36%)
     
  • FTSE 100

    6,925.50
    -74.58 (-1.07%)
     
  • Nikkei 225

    29,100.38
    -584.99 (-1.97%)
     

BioMarin: 4Q Earnings Snapshot

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

SAN RAFAEL, Calif. (AP) _ BioMarin Pharmaceutical Inc. (BMRN) on Thursday reported fourth-quarter profit of $22.1 million.

The San Rafael, California-based company said it had net income of 12 cents per share. Earnings, adjusted for one-time gains and costs, were 21 cents per share.

The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of 17 cents per share.

The rare disease biopharmaceutical posted revenue of $452.1 million in the period, also surpassing Street forecasts. Ten analysts surveyed by Zacks expected $447.2 million.

For the year, the company reported net income of $859.1 million, or $4.53 per share, swinging to a profit in the period. Revenue was reported as $1.86 billion.

BioMarin expects full-year revenue in the range of $1.75 billion to $1.85 billion.

BioMarin shares have fallen almost 7% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $81.76, a decline of 10% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BMRN at https://www.zacks.com/ap/BMRN